DocMorris AG (ZRSEF) Stock Price & Analysis
DocMorris AG (ZRSEF) — price $10.24 (0.00%), as of the Nov 19, 2026 trading session; market cap $522M.
Educational signal · not a buy or sell recommendation · How to read this
DocMorris AG · ZRSEF
DocMorris AG operates a dual business model encompassing e-commerce pharmacies and a wholesale distribution network for medical and pharmaceutical goods across Switzerland and internationally. The company offers consumer health, beauty, and personal care items, alongside medication management services, utilizing brands like Zur Rose and DocMorris.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.24 | |
| Change on the day | 0.00% | |
| Market capitalisation | $522M | — |
| Shares traded on the day | 10 |
Price & events
Other perspectives
Council score for DocMorris AG (ZRSEF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is DocMorris AG (ZRSEF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. DocMorris AG (ZRSEF) is the company analyzed here. It employs 1,097 people. In Q2 FY2026 it reported revenue of CHF 596M and net income of -CHF 53M. The market values it at $522M.
What do the latest results show for DocMorris AG (ZRSEF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of CHF 596M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | CHF 596M | -CHF 53M | -CHF 1.08 (diluted) |
| Q4 FY2025 | CHF 584M | -CHF 73M | -CHF 0.49 (diluted) |
| Q2 FY2025 | CHF 541M | -CHF 62M | -CHF 2.11 (diluted) |
| Q4 FY2024 | CHF 521M | -CHF 59M | -CHF 5.03 (diluted) |
What are the financial strengths and risks for DocMorris AG (ZRSEF)?
Short answer · as of
The distress and quality screens read Altman Z 0.63 · Piotroski F 3. Trailing ratios: ROE -32.8% · ROA -16.2% · current ratio 1.87 · earnings yield -14.2% · free-cash-flow yield 3.9%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.63 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-32.8%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZRSEF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZRSEF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Investor Questions: ZRSEF Stock
These answers are editorial: 1 of these 8 answers is drawn from the ZRSEF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ZRSEF a good stock to buy?
Stock Expert AI does not rate ZRSEF buy, sell or hold. DocMorris AG has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZRSEF stock price today?
The last price recorded for DocMorris AG (ZRSEF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does DocMorris AG do?
DocMorris AG, headquartered in Frauenfeld, Switzerland, operates a comprehensive dual business model within the healthcare sector. The company manages both e-commerce pharmacies, offering a wide range of prescription and over-the-counter medications, and a robust wholesale distribution network for medical and pharmaceutical goods.
What are the key factors to evaluate for ZRSEF?
Evaluate ZRSEF on fundamentals, analyst consensus, and risk factors. The market for digital health services is expanding rapidly, offering long-term growth potential. Not financial advice.
How frequently does ZRSEF data refresh on this page?
ZRSEF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZRSEF's recent stock price performance?
DocMorris AG (ZRSEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition in the German-speaking market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZRSEF overvalued or undervalued right now?
DocMorris AG (ZRSEF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ZRSEF before investing?
Before investing in DocMorris AG (ZRSEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com